Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 22nd Century Group, Inc.XXII · Entity 8519 | Chief Financial Officer | March 21, 2022 | March 23, 2022 |
| Carisma Therapeutics Inc.SESN · Entity 74418 | Chief Financial Officer | February 21, 2019 | February 25, 2019 |
| Immunome Inc.IMNM · Entity 4219 | Chief Financial Officer | October 01, 2020 | October 05, 2020 |
| Nauticus Robotics, Inc.CLAQU · Entity 8200 | Chief Financial Officer | July 14, 2021 | July 28, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
22nd Century Group, Inc.
Report date March 21, 2022 · Filed March 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,722 |
Reported balance
After 2022-03-21 transaction · row 1
1 source rowRow 1 · 2022-03-21 · Grant · Acquired 124,722 · Balance 124,722 F1: The restricted stock units vest 1/3 per year on March 21, 2023, 2024 and 2025, subject to continued service with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest 1/3 per year on March 21, 2023, 2024 and 2025, subject to continued service with the Company.
Carisma Therapeutics Inc.
Report date February 21, 2019 · Filed February 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.83 · Expires 2029-02-21 | Direct | 178,500 |
Reported balance
After 2019-02-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-21 · Grant · Acquired 178,500 · Balance 178,500 F1: On February 21, 2019, the reporting person was awarded options to purchase 178,500 shares of the common stock of Sesen Bio, Inc. (the "Company"), which options vest 6.25% every three months over four years provided the reporting person is employed by the Company at each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 21, 2019, the reporting person was awarded options to purchase 178,500 shares of the common stock of Sesen Bio, Inc. (the "Company"), which options vest 6.25% every three months over four years provided the reporting person is employed by the Company at each such vesting date.
Immunome Inc.
Report date October 01, 2020 · Filed October 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2030-10-01 | Direct | 104,802 |
Reported balance
After 2020-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-01 · Grant · Acquired 104,802 · Balance 104,802 F1: Twenty-five percent (25%) of the shares subject to the option shall vest on October 1, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2030-10-01 | Direct | 7,681 |
Reported balance
After 2020-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-01 · Grant · Acquired 7,681 · Balance 7,681 F2: The shares subject to the option shall vest on October 1, 2025, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the shares subject to the option shall vest on October 1, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
F2: The shares subject to the option shall vest on October 1, 2025, subject to the Reporting Person continuing to provide service through each such date.
Nauticus Robotics, Inc.
Report date July 14, 2021 · Filed July 28, 2021
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 21, 2022 Filed Mar 23, 2022 17:00 UTC | 22nd Century Group, Inc. XXII · Entity 8519 | GrantCommon Stock | 124,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007395 · doc1.xml · nonDerivative · entry 1 Fitzgerald Richard F · CIK 0001459933 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,722 F1 · shares: The restricted stock units vest 1/3 per year on March 21, 2023, 2024 and 2025, subject to continued service with the Company. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:40 UTC | Immunome Inc. IMNM · Entity 4219 | GrantEmployee Stock Option (right to buy) · Derivative | 7,681 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053654 · doc4.xml · derivative · entry 2 Fitzgerald Richard F · CIK 0001459933 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,681 Underlying: Common Stock · 7,681 shares Expires 2030-10-01 F2 · derivative.exercise_date: The shares subject to the option shall vest on October 1, 2025, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:40 UTC | Immunome Inc. IMNM · Entity 4219 | GrantEmployee Stock Option (right to buy) · Derivative | 104,802 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053654 · doc4.xml · derivative · entry 1 Fitzgerald Richard F · CIK 0001459933 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,802 Underlying: Common Stock · 104,802 shares Expires 2030-10-01 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on October 1, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 16:09 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantEmployee Stock Option (Right to Buy) · Derivative | 178,500 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001485003-19-000009 · wf-form4_155112897763761.xml · derivative · entry 1 Fitzgerald Richard F · CIK 0001459933 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,500 Underlying: Common Stock · 178,500 shares Expires 2029-02-21 F1 · derivative.exercise_date: On February 21, 2019, the reporting person was awarded options to purchase 178,500 shares of the common stock of Sesen Bio, Inc. (the "Company"), which options vest 6.25% every three months over four years provided the reporting person is employed by the Company at each such vesting date. Read SEC document |
| April 09, 2018 Filed Apr 11, 2018 17:02 UTC | Carisma Therapeutics Inc. EBIO · Entity 74418 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001485003-18-000045 · wf-form4_152348041848084.xml · derivative · entry 1 Fitzgerald Richard F · CIK 0001459933 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-04-08 F1 · derivative.exercise_date: On April 9, 2018, the reporting person was awarded options to purchase 200,000 shares of common stock of Eleven Biotherapeutics, Inc. (the "Company"), which options vest 6.25% every three months over four years, provided the reporting person is employed by the Company on each such vesting date. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 16:55 UTC | Carisma Therapeutics Inc. EBIO · Entity 74418 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001485003-18-000008 · wf-form4_151691732200655.xml · derivative · entry 1 Fitzgerald Richard F · CIK 0001459933 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-01-22 F1 · derivative.exercise_date: 25% of the shares subject to such option shall vest on the first anniversary of the date of grant of the option and an additional 6.25% of the shares underlying the option shall vest at the end of each successive three-month period thereafter until the fourth anniversary of the date of grant of the option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.